KALA - Kala Pharmaceuticals Inc logo

KALA

Kala Pharmaceuticals Inc

Net income grew 100% of years5Y
Hold

KALA BIO, Inc. is a clinical-stage biopharmaceutical company developing therapies for rare and severe eye diseases. Its lead products include KPI-012 for persistent corneal epithelial defects and KPI-014 for rare inherited retinal diseases.

โš•๏ธ Healthcare NASDAQ Listed 2017 $ USD
$1,000 invested 5 years ago โ†’$0today

Score Overview

1 Year
Scoreโ€”
Net Growth27.15%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score5.7
Net Growth86.22%
Net TrendEvery year
Net Income Consistencyโ€”
Rev Growth-100.00%
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth53.44%
Net Trend56%
Net Income Consistency
Rev Growthโ€”
Rev Trend33%
Revenue Consistency

See the full market ranking โ†’

Kala Pharmaceuticals Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 6M to $ 0.00 and net income went from -$ 104M to -$ 26M. Revenue increased in 0 of those 5 years; net income in every one.

Kala Pharmaceuticals Inc currently holds a 5-year HDB Score of 5.7 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 0.88โ€”
1 Year2025-08-12
$ 372.00-99.76%
5 Years2021-08-12
$ 7.8K-99.99%
All Time2017-07-20
$ 46.23K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 19M$ 8M
2025$ 0.00-$ 26M$ 7M
2024$ 0.00-$ 38M$ 51M
2023$ 0.00-$ 42M$ 50M
2022$ 3M-$ 44M$ 70M
2021$ 11M-$ 142M$ 92M
2020$ 6M-$ 104M$ 153M
2019$ 6M-$ 94M$ 85M
2018$ 0.00-$ 66M$ 170M
IPO2017$ 0.00-$ 42M$ 114M

Explore beyond KALA

You're looking at Kala Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies